Top

Published in:

01-12-2020 | Breast Cancer | ASO Author Reflections

ASO Author Reflections: Time for a Paradigm Shift in “Hormone Receptor Positive” Invasive Breast Cancer?

Author: Christine Dauphine, MD

Published in: Annals of Surgical Oncology | Special Issue 3/2020

Excerpt

The Current National Comprehensive Cancer Network1 and American Society of Clinical Oncology2 clinical practice guidelines outline treatment algorithms for “hormone receptor positive” human epidermal growth factor receptor 2 (HER2)-negative invasive breast cancers, not specifically accounting for the estrogen receptor (ER) and progesterone receptor (PR) status individually. This is largely due to the fact that clinical trials have routinely grouped cancers as “hormone receptor positive” regardless of whether one or both ER and PR stain positive in at least 1% of cells on immunohistochemical evaluation of tissue samples. …

National Comprehensive Cancer Network Breast Cancer (Version 3.2020). Invasive Breast Cancer, Systemic Adjuvant Treatment (BINV-4). https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed July 7, 2020.

American Society of Clinical Oncology Practice Guidelines. Role of patient and disease factors in adjuvant systemic therapy decision-making for early-stage, operable breast cancer. https://www.asco.org/research-guidelines/quality-guidelines/guidelines/breast-cancer#/10696. Accessed July 7, 2020.

Dauphine C, Moazzez A, Neal J, Chlebowski R, Ozao-Choy J. Single hormone receptor positive breast cancers have distinct characteristics and survival. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08898-5.

Prat A, Cheang MC, Martin M, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol. 2013;31(2):203–9.CrossRef

Title: ASO Author Reflections: Time for a Paradigm Shift in “Hormone Receptor Positive” Invasive Breast Cancer?
Author: Christine Dauphine, MD
Publication date: 01-12-2020
Publisher: Springer International Publishing
Keywords: Breast Cancer
Breast Cancer
Published in: Annals of Surgical Oncology / Issue Special Issue 3/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-020-08950-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

ASO Author Reflections: Time for a Paradigm Shift in “Hormone Receptor Positive” Invasive Breast Cancer?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 3/2020

ASO Author Reflections: Which of Smoking Duration or Smoking Intensity Contributes to Poor Prognosis After Resection of Non-small Cell Lung Cancer?

Correction to: Internal Mammary Sentinel Lymph Node Biopsy in Clinically Axillary Lymph Node-Positive Breast Cancer: Diagnosis and Implications for Patient Management

ASO Author Reflections: Sentinel Lymph Node Removal After Neoadjuvant Chemotherapy in Clinically Node-Negative Patients Can Stop After Removal of Three Lymph Nodes

Correction to: Primary Tumor Location and Outcomes After Cytoreductive Surgery and Intraperitoneal Chemotherapy for Peritoneal Metastases of Colorectal Origin

Correction to: ASO Author Reflections: Minimally Invasive Esophagectomy for Esophageal Cancer in the Prone and Lateral Position

ASO Author Reflections: Is Breast Cancer Dissemination Lymphatic, Hematogenous, or Both; and Does It Matter?